Literature DB >> 31353980

Paroxysmal movement disorders - practical update on diagnosis and management.

Claudio M De Gusmao1,2, Laura Silveira-Moriyama2,3,4.   

Abstract

Introduction: Paroxysmal dyskinesias and episodic ataxias are often caused by mutations in genes related to cell membrane and synaptic function. Despite the exponential increase in publications of genetically confirmed cases, management remains largely clinical based on non-systematic evidence. Areas covered: The authors provide a historical and clinical review of the main types of paroxysmal dyskinesias and episodic ataxias, with recommendations for diagnosis and management of patients suffering from these conditions. Expert opinion: After secondary paroxysmal dyskinesias, the most common paroxysmal movement disorders are likely to be PRRT2-associated paroxysmal kinesigenic dyskinesias, which respond well to small doses of carbamazepine, and episodic ataxia type 2, which often responds to acetazolamide. Familial paroxysmal non-kinesigenic dyskinesias are largely caused by mutations in PNKD and have poor response to therapy but improve with age. Exercise-induced dyskinesias are genetically heterogeneous, caused by disorders of glucose transport, mitochondrial function, dopaminergic pathways or neurodegenerative conditions amongst others. GNAO1 and ADCY5 mutations can also cause paroxysmal movement disorders, often in the context of ongoing motor symptoms. Although a therapeutic trial is justified for classic cases and in limited resource settings, genetic testing may help direct initial or rescue therapy. Deep brain stimulation may be an option for severe cases.

Entities:  

Keywords:  Acetazolamide; antiepileptic drugs; episodic ataxias; paroxysmal dyskinesias; paroxysmal movement disorders

Year:  2019        PMID: 31353980     DOI: 10.1080/14737175.2019.1648211

Source DB:  PubMed          Journal:  Expert Rev Neurother        ISSN: 1473-7175            Impact factor:   4.618


  6 in total

1.  Screening of the TMEM151A Gene in Patients With Paroxysmal Kinesigenic Dyskinesia and Other Movement Disorders.

Authors:  Ling-Yan Ma; Lin Han; Meng Niu; Lu Chen; Ya-Zhen Yu; Tao Feng
Journal:  Front Neurol       Date:  2022-05-30       Impact factor: 4.086

2.  Phenotypic and Genetic Complexity in Pediatric Movement Disorders.

Authors:  Min-Jee Kim; Mi-Sun Yum; Go Hun Seo; Tae-Sung Ko; Beom Hee Lee
Journal:  Front Genet       Date:  2022-06-01       Impact factor: 4.772

3.  FGF14-related episodic ataxia: delineating the phenotype of Episodic Ataxia type 9.

Authors:  Julie Piarroux; Florence Riant; Véronique Humbertclaude; Ganaelle Remerand; Jessica Hadjadj; Franck Rejou; Christine Coubes; Lucile Pinson; Pierre Meyer; Agathe Roubertie
Journal:  Ann Clin Transl Neurol       Date:  2020-03-12       Impact factor: 4.511

4.  Paroxysmal Kinesigenic Dyskinesia Caused by 16p11.2 Microdeletion and Related Clinical Features.

Authors:  Yu-Lan Chen; Dian-Fu Chen; Hua-Zhen Ke; Shao-Yun Zhao; Hong-Fu Li; Zhi-Ying Wu
Journal:  Neurol Genet       Date:  2022-02-17

5.  Varied phenotypic spectrum presenting of paroxysmal exercise-induced dyskinesia: a Turkish family with SLC2A1 mutation.

Authors:  Murat Gultekin; Muhammet Ensar Dogan; Gulsah Simsir; Ayse Nazlı Basak
Journal:  Neurol Sci       Date:  2021-07-19       Impact factor: 3.307

6.  Disruption of gray matter morphological networks in patients with paroxysmal kinesigenic dyskinesia.

Authors:  Xiuli Li; Du Lei; Running Niu; Lei Li; Xueling Suo; Wenbin Li; Chen Yang; Tianhua Yang; Jiechuan Ren; Walter H L Pinaya; Dong Zhou; Graham J Kemp; Qiyong Gong
Journal:  Hum Brain Mapp       Date:  2020-10-15       Impact factor: 5.399

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.